Complementary and antagonistic effects of combined glucagon‐like peptide‐2 and glucagon‐like peptide‐1 receptor agonist administration on parameters relevant to short bowel syndrome

Short bowel syndrome (SBS) is characterized by malabsorption requiring parenteral nutrition. The intestinotrophic glucagon-like peptide (GLP)-2 receptor agonist, h[Gly2]GLP2, is used to treat patients with SBS. Evidence suggests that GLP-1 receptor agonists such as exendin-4 (Ex4) may be beneficial in SBS given their ability to increase intestinal growth and delay gastric emptying (GE).Intestinal growth, body weight (BW), food intake (FI), GE,...